aod9604 clinical trials weight loss efficacy side effects AOD 9604: The Complete Evidence-Based Guide to the F AOD‑9604 Peptide for Fat Loss:
Description
The consistency of this finding across multiple independent trials, different dose ranges, and various administration routes provides robust evidence that the peptide does not affect the growth hormone/IGF-1 axis
Pushing through excessive fatigue during aggressive fat loss protocols leads to overtraining syndrome, which actually increases muscle catabolism and slows fat loss
This was because the drug did not significantly reduce weight in 536 subjects over the course of 24 weeks 2
2002;282(5 ): R136873
When paired with strength training and adequate protein, it does not appear to cause muscle loss
